The Executive Function Toolkit: CBG and THCV for ADHD Management

CBG: The Neural Filter for Brain Noise

CBG acts as a neurological smoother. It may mimic the action of non-stimulant interventions by targeting alpha-2 adrenoceptors, which can help reduce background chatter in the prefrontal cortex.

CBG supports the inhibition of GABA reuptake. By potentially increasing GABA levels, it may help quiet emotional dysregulation and Rejection Sensitive Dysphoria (RSD) that often accompany ADHD. Many describe the sensation as putting on noise-canceling headphones for internal thoughts. This cannabinoid may be a useful choice for those who feel overwhelmed by multiple options and struggle to initiate tasks.

THCV: The Spark for Task Initiation

THCV provides a distinct, clear-headed energy. Unlike THC, which can cause mental fog in some users, low doses of THCV act as a CB1 antagonist. By switching the receptor off rather than on, it may help prevent the appetite stimulation and heavy sedation often associated with standard cannabis use.

THCV may encourage a sense of urgency and motivation. It supports glucose metabolism, which may assist in preventing afternoon sugar crashes that can exacerbate ADHD symptoms. It is often utilized by those who struggle with low arousal, daytime sleepiness, and general mental sluggishness.

Memory Anchors: Pinene and Eucalyptol

ADHD and cannabis use can both contribute to short-term memory gaps. You can counter this by selecting products high in specific "memory anchor" terpenes.

Alpha-Pinene acts as an acetylcholinesterase inhibitor. It may prevent the breakdown of the neurotransmitters responsible for memory formation. Eucalyptol (Cineole) supports cerebral blood flow. Pairing these two creates a cerebral oxygenation stack. This combination may help the brain receive the oxygenated blood required for high-level executive function while helping to mitigate those "where did I put my keys?" moments.

Stacking Protocols for ADHD Subtypes

ADHD presents differently in every individual. Your cannabinoid ratio should reflect your specific symptom profile.

Primarily Inattentive Protocol

Inattentive ADHD involves a lack of "mental friction," where thoughts slide away before you can capture them.

• The Stack: 5mg THCV + 2.5mg THC + 10mg CBD.
• Terpene Target: Limonene and Eucalyptol.
• The Sensation: This may create upward pressure to keep the brain engaged without the racing heart associated with caffeine.

Primarily Hyperactive-Impulsive Protocol

This type feels like being "driven by a motor." The goal is supporting "braking power."

• The Stack: 10mg CBG + 10mg CBD + 1mg THC.
• Terpene Target: Linalool and Beta-Caryophyllene.
• The Sensation: This may engage the central nervous system's brakes, allowing for a pause before acting.

Safety and the Dopamine Ceiling

ADHD brains are naturally dopamine-seeking. While THC causes a dopamine flood, high-potency concentrates can lead to downregulation, where the brain reduces its natural receptors to compensate for the flood—eventually resulting in "Amotivational Syndrome."

Maintain a 4:1 ratio of non-intoxicating cannabinoids to THC. Use four parts CBD, CBG, or THCV for every one part THC. This dilution may maintain the functional focus-effect while keeping your dopamine receptors sensitive. It helps prevent the perceived benefit from disappearing after a few weeks of consistent use.

The 5:00 PM Pivot: Context Switching

ADHD individuals often struggle with "context switching," or moving from high-pressure work mode to home life. Alcohol is a common but often counterproductive choice for this transition because it disrupts REM sleep and further degrades executive function.

Utilize Beta-Caryophyllene for your evening transition. Caryophyllene is a terpene that acts similarly to a cannabinoid by binding to CB2 receptors. It may physically relax the body and reduce "stimulant jaw-clenching" without turning off cognitive faculties. It allows for decompression and engagement with social obligations without the irritability that often follows a day of intense focus.

Strategic Selection Tips

Ignore "Sativa" or "Indica" labels. These are merely botanical descriptions of how the plant grows, not how it affects your neurochemistry.

Review the Certificate of Analysis (COA) for minor cannabinoid content. Seek out flower or tinctures that test for at least 0.5% CBG or THCV. If a product contains high levels of Myrcene without Pinene, it may increase "fog" rather than clearing it. Always check the lab results to ensure you are building a functional toolkit rather than relying on unverified products.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

2. Colasanti BK. (1990). A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol. 6(4):259-69. PubMed

3. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM. (2005). Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 27(6):799-810. PubMed

4. Wargent ET, Zaibi MS, Sherwood C, Hayter DG, Archer CA, Chambers AP, Morgan I, Stocker CJ, Matias I, Marsicano G, Cota D, Hislop DC, Arch JR, Cawthorne MA. (2013). The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 3:e68. PubMed

5. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Claro E, Di Marzo V, Izzo AA. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 85(9):1306-16. [PubMed](https://pubmed.ncbi.nlm.